Ribomic Inc. announced that the first case has been registered at Tokyo Medical and Dental University Hospital for an observational study to obtain basic clinical data including height growth and to select appropriate subjects for continuously scheduled RBM-007 early phase 2 study in Achondroplasia patients. Furthermore, RIBOMIC has received approval from the Pharmaceuticals and Medical Devices Agency (PMDA) to conduct an early Phase 2 study of exploratory investigation for the safety and efficacy of RBM-007 in achondroplasia pediatric patients, as well as following extension study. Therefore, RIBOMIC is planning to proceed with those studies following the observational study.